Tag: Targeted therapy

First approved by the FDA in 2017 for mantle cell lymphoma, **calquence** (acalabrutinib) is a targeted oral medication used to treat certain B-cell malignancies. It is not a traditional chemotherapy drug but a Bruton's tyrosine kinase (BTK) inhibitor, a class of targeted therapies that work by interrupting specific signaling pathways within cancer cells. This targeted approach aims to limit the negative effects on healthy cells, offering a more precise treatment method.

For many common cancers, adjuvant chemotherapy after surgery can reduce the risk of recurrence by around 30% [1.2.3]. So, **what drugs shrink tumors** and how do they work? The answer lies in several classes of powerful medications designed to attack cancer cells.

Affecting approximately 1 in 5,000 to 10,000 people, venous malformations (VMs) are congenital vascular lesions that pose significant treatment challenges. Understanding **what medication is used for venous malformation** is crucial for patients, as pharmacological interventions play an increasingly important role, especially for complex or widespread cases where surgery or local treatments are not feasible.

With a significant presence in the biopharmaceutical industry, Incyte has developed a diverse portfolio of treatments aimed at areas of high unmet medical need, particularly oncology, inflammation, and dermatology. Understanding what drugs does Incyte make involves exploring their proprietary therapies as well as co-marketed and licensed products.

Erdafitinib is the official generic name for the targeted cancer drug sold under the brand name Balversa. Despite being approved by the FDA in 2019, a generic version is not yet available on the market due to patent protection. This article explores the specifics of erdafitinib, its brand name, and the timeline for potential generic availability.

Made from living organisms, biologics are thousands of times larger and more complex than traditional small-molecule drugs like aspirin. This fundamental difference in origin and structure is key to understanding how are biologics different from other drugs and why they represent a paradigm shift in modern medicine.

With a market valued at over $500 billion in 2023, biologics are revolutionizing modern medicine. Their distinctiveness lies in what makes biologics unique: their origin from living systems, large and complex molecular structure, and highly specific mechanism of action, differentiating them fundamentally from traditional chemical drugs.

Ocrevus (ocrelizumab) was the first and only therapy approved by the U.S. Food and Drug Administration (FDA) for both relapsing and primary progressive forms of multiple sclerosis in adults. But what drug category is Ocrevus? It belongs to a class of highly specific, targeted immunotherapies known as anti-CD20 monoclonal antibodies, which selectively deplete certain immune cells believed to drive MS pathology.

Originally approved for non-Hodgkin's lymphoma, rituximab is increasingly used for autoimmune diseases, but is rituximab considered an immunosuppressant? The answer lies in its targeted B-cell depletion mechanism, which directly impacts a core component of the immune system.

Over the past several decades, monoclonal antibody (mAb) therapies have fundamentally transformed the landscape of medical treatment, particularly within oncology. A common use of monoclonal antibodies in medicine is as a highly targeted therapy for certain types of cancer and autoimmune diseases by precisely targeting specific molecules.